Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Chicago
ImmunityBio, Inc.
Ohio State University Comprehensive Cancer Center
Bristol-Myers Squibb
Yale University
Sarcoma Oncology Research Center, LLC